Securing a positive recommendation from the National Institute for Health and Care Excellence (NICE)...
Read moreWhen bringing a new health technology to market in England, pharmaceutical and biotech companies mus...
Read moreThe key to pricing success for any pharmaceutical product is effectively exhibiting the asset’...
Read moreThe increasing complexity of bringing innovative therapies to market across various jurisdictions pr...
Read moreWith the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...
Read moreAs the regulatory and market access landscape continues to evolve across Europe, timely and strategi...
Read moreIn the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu...
Read moreThe long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...
Read moreThe advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...
Read moreThe population, intervention, comparator, and outcomes (PICO) element of the upcoming EU Joint Clini...
Read more